Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Operations: 2010-2025

Historic Cash from Operations for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$3.6 million.

  • Lineage Cell Therapeutics' Cash from Operations rose 37.52% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.4 million, marking a year-over-year increase of 10.45%. This contributed to the annual value of -$23.1 million for FY2024, which is 19.16% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Cash from Operations stood at -$3.6 million, which was up 34.72% from -$5.5 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Cash from Operations registered a high of $21.9 million during Q1 2022, and its lowest value of -$11.2 million during Q1 2023.
  • Over the past 3 years, Lineage Cell Therapeutics' median Cash from Operations value was -$5.8 million (recorded in 2024), while the average stood at -$6.0 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Cash from Operations surged by 395.04% in 2022 and then crashed by 151.32% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Cash from Operations (Quarterly) stood at -$5.9 million in 2021, then slumped by 41.38% to -$8.3 million in 2022, then grew by 27.51% to -$6.0 million in 2023, then dropped by 5.43% to -$6.3 million in 2024, then spiked by 37.52% to -$3.6 million in 2025.
  • Its Cash from Operations stands at -$3.6 million for Q3 2025, versus -$5.5 million for Q2 2025 and -$4.9 million for Q1 2025.